Itolizumab
- All
- News
- Videos
-
Biocon Says Clinical Study For Drug Itolizumab Initiated After Drug Regulator's Approval
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients
The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in the country.
-
Psoriasis Injection Cleared For Limited Use To Treat COVID Patients: Drug Controller
India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
-
Biocon to launch psoriasis drug novel biologic in July
Biotechnology major Biocon plans to launch in July its novel biologic drug Itolizumab branded as 'Alzumab' to be used for the treatment of chronic plaque psoriasis in the country.
-
Biocon gets approval to market anti-psoriasis drug
Biotechnology major Biocon today said it has received approval from Drug Controller General of India (DCGI) to market its product 'Itolizumab', used in the treatment of psoriasis.
-
Biocon Says Clinical Study For Drug Itolizumab Initiated After Drug Regulator's Approval
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said clinical study for its biologic drug Itolizumab for possible indication in autoimmune disease Lupus Nephritis has been initiated in India after approval from the Drugs C
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients
The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in the country.
-
Psoriasis Injection Cleared For Limited Use To Treat COVID Patients: Drug Controller
India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
-
Biocon to launch psoriasis drug novel biologic in July
Biotechnology major Biocon plans to launch in July its novel biologic drug Itolizumab branded as 'Alzumab' to be used for the treatment of chronic plaque psoriasis in the country.
-
Biocon gets approval to market anti-psoriasis drug
Biotechnology major Biocon today said it has received approval from Drug Controller General of India (DCGI) to market its product 'Itolizumab', used in the treatment of psoriasis.
